LONDON (Reuters) - An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds ($704,630) a year may be worth using in babies with a rare disorder but does not represent good value for all patients, Britain's healthcare cost watchdog said.
http://ift.tt/xePdMM
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire